全文获取类型
收费全文 | 267篇 |
免费 | 10篇 |
国内免费 | 1篇 |
出版年
2021年 | 3篇 |
2016年 | 6篇 |
2015年 | 6篇 |
2014年 | 3篇 |
2013年 | 6篇 |
2012年 | 11篇 |
2011年 | 13篇 |
2010年 | 5篇 |
2009年 | 5篇 |
2008年 | 9篇 |
2007年 | 10篇 |
2006年 | 14篇 |
2005年 | 9篇 |
2004年 | 13篇 |
2003年 | 8篇 |
2002年 | 19篇 |
2001年 | 11篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 3篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 9篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1988年 | 4篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1973年 | 2篇 |
1966年 | 2篇 |
1964年 | 2篇 |
1963年 | 9篇 |
1962年 | 10篇 |
1961年 | 3篇 |
1960年 | 2篇 |
1957年 | 3篇 |
1956年 | 2篇 |
1955年 | 3篇 |
1954年 | 2篇 |
1951年 | 4篇 |
1950年 | 2篇 |
1943年 | 4篇 |
1939年 | 2篇 |
1931年 | 2篇 |
1923年 | 1篇 |
1918年 | 1篇 |
1917年 | 1篇 |
1902年 | 1篇 |
1875年 | 1篇 |
排序方式: 共有278条查询结果,搜索用时 15 毫秒
271.
William R. Vogler Alfred A. Bartolucci George A. Omura Donald Miller Richard V. Smalley William H. Knospe Alice S. Goldsmith Yick-Kwong Chan Scott Murphy Writing Committee for Southeastern Cancer Study Group 《Cancer immunology, immunotherapy : CII》1978,3(3):163-170
Summary The Southeastern Cancer Study Group conducted a randomized clinical trial in acute myeloblastic leukemia and the blastic phase of chronic myelocytic leukemia to compare: Two induction programs (Schedule A) cytosine arabinoside and 6-thioguanine or (Schedule B) cytosine arabinoside, 6-thioguanine and daunorubicin; two consolidation programs (Schedule C) continuation of induction programs at a reduced dose or (Schedule D) a combination of cyclophosphamide, methotrexate and vincristine; and two maintenance programs — (Schedule E) 1 month of BCG, followed by methotrexate or (Schedule F) methotrexate. Over a 3 year period 372 patients were entered and 295 were judged evaluable. None of 11 patients with blastic phase of chronic myelocytic leukemia responded. There were no significant differences between the schedules in the number of patients with acute myeloblastic leukemia achieving complete remissions (37%, Schedule A vs. 41% Schedule B). The relapse rates on consolidation were similar (43%, Schedule C and 39%, Schedule D). BCG significantly prolonged the duration of first remission following consolidation (P<0.05) from 13.0–23.9 weeks. Survival was not significantly prolonged (92.7 weeks vs. 71.7 weeks). There were no serious complications from BCG therapy.
Contributors. The following members of the Southeastern Cancer Study Group participated in this study: John T. Carpenter, John R. Durant, Richard Gams, William J. Hammack, George A. Omura, Gayle Roberts, University of Alabama School of Medicine, Birmingham, Alabama; Harold Silberman, Donald S. Miller, Duke University School of Medicine, Durham, North Carolina; William B. Kremer, Durham Veterans Administration Hospital, Durham, North Carolina; Evert A. Bruckner, Lawrence E. Cooper, Charles C. Corley, Joseph E. Hardison, Charles M. Huguley, Jr., James Keller, Mason G. Robertson, John D. Schmale, Charles Vogel, W. R. Vogler, William H. Whaley, E. F. Winton, Emory University School of Medicine, Atlanta, Georgia; Chan Kon Chin, Guy Faguet, Claude-Starr Wright, Medical College of Georgia, Augusta, Georgia; Y. S. Ahn, Howard E. Lessner, University of Miami School of Medicine, Miami, Florida; Dov Gorshein, Scott Murphy, Presbyterian University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; William E. Barry, Sharon P. Fischer, Rosaline R. Joseph, Richard V. Smalley, Temple University School of Medicine, Philadelphia, Pennsylvania; Virgil Loeb, Jr., Cary Presant, Edward Reinhard, Shabbir H. Safdar, Washington University School of Medicine, St. Louis, Missouri; Norman Maldonado, Enrique Velez-Garcia, University of Puerto Rico School of Medicine, San Juan, Puerto Rico; S. A. Gregory, William H. Knospe, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois; Stephen Krauss, University of Tennessee Memorial Research Center, Knoxville, Tennessee; Karl Tornyos, New Orleans Veterans Hospital, New Orleans, Louisiana; W. B. Forman, R. W. Kellermeyer, A. Rassiga, Case Western Reserve University School of Medicine, Cleveland, Ohio; William R. Arrowsmith, George Porter, Donald M. Samples, Ochsner Clinic, New Orleans, Louisiana; Lois W. Dow, Charles L. Neely, University of Tennessee School of Medicine, Memphis, Tennessee; G. O. Broun, Jr., St. Louis University School of Medicine, St. Louis, Missouri 相似文献
272.
The advantages of the oral administration of cortisone, when compared with cortisone given intramuscularly, include the more rapid appearance of therapeutic effects, which is of importance in the therapy of acute disease, and the faster dissipation of effects when the hormone is discontinued, which is of value when dangerous reactions occur. Oral dose schedules depend upon the degree of urgency or chronicity of the treated disease. In acute diseases the therapeutic results, in general, were disappointing. Cortisone may be of greater value in the long-term maintenance treatment of certain chronic diseases. By long-term therapy the authors mean practically continuous treatment until either the disease goes into spontaneous remission or undesirable effects of the drug require cessation of treatment. Critical selection of patients and constant supervision of therapy are vital to the successful administration of cortisone. Even with these precautions, however, the therapeutic use of cortisone must be regarded as experimental until the passage of time permits better appraisal of harmful effects. 相似文献
273.
274.
275.
276.
277.
278.